Last reviewed · How we verify

NCT04354688: Apple

T3 Certain Tapered With DCD vs T3 Certain Tapered Non-DCD

Completed NA Last updated 23 July 2024
What this trial tests

NA trial testing T3 Certain Tapered Implant in Edentulous Jaw in 60 participants. Completed in 30 June 2024.

Timeline
19 October 2019
Primary endpoint
1 February 2024
30 June 2024

Quick facts

Lead sponsorZimVie
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment60
Start date19 October 2019
Primary completion1 February 2024
Estimated completion30 June 2024
Sites2 locations across Chile, Greece

Drugs / interventions tested

Conditions studied

Sponsor

ZimVie — full company profile →

Who can join

18 and older, any sex, with Edentulous Jaw. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This will be a prospective, randomized multicenter study to determine the safety and efficacy of the T3 Certain Tapered with DCD as compared to T3 Certain Tapered without DCD. All implants will be placed in the maxilla or mandible in a single stage manner and loaded with prosthesis after 6 weeks of healing. Final restorations will take place no later than 4 months following implant placement surgery. The implants will be evaluated yearly for 2 years.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Edentulous Jaw

Currently open trials in the same condition.

Other ZimVie trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04354688.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing